Vaccinex, Inc. (VCNX) stock
VCNXOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q4 FY2024, quarter ended Dec 31, 2024Last filing: 10-K on Apr 15, 2025
$1.00−0.01 (-0.99%)
Close on Oct 19, 2026Market cap $3.22MP/E –Yield –
Vaccinex free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Vaccinex's free cash flow for the twelve months ending Dec 31, 2024 was -$16.21M. For fiscal 2024 it was -$16.21M. The highest annual figure on record is -$16.21M in fiscal 2024.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | -$16.21M | – |
| FY2023 | Dec 31, 2023 | -$21.45M | – |
| FY2022 | Dec 31, 2022 | -$19.17M | – |
| FY2021 | Dec 31, 2021 | -$25.33M | – |
| FY2020 | Dec 31, 2020 | -$28.94M | – |
| FY2019 | Dec 31, 2019 | -$30.79M | – |
| FY2018 | Dec 31, 2018 | -$25.51M | – |
| FY2017 | Dec 31, 2017 | -$21.46M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2024 | Dec 31, 2024 | -$3.93M | – |
| Q3 FY2024 | Sep 30, 2024 | -$3.22M | – |
| Q2 FY2024 | Jun 30, 2024 | -$4.43M | – |
| Q1 FY2024 | Mar 31, 2024 | -$4.63M | – |
| Q4 FY2023 | Dec 31, 2023 | -$7.74M | – |
| Q3 FY2023 | Sep 30, 2023 | -$3.11M | – |
| Q2 FY2023 | Jun 30, 2023 | -$5.51M | – |
| Q1 FY2023 | Mar 31, 2023 | -$5.09M | – |
| Q4 FY2022 | Dec 31, 2022 | -$4.60M | – |
| Q3 FY2022 | Sep 30, 2022 | -$4.20M | – |
| Q4 FY2021 | Dec 31, 2021 | -$5.14M | – |
| Q3 FY2021 | Sep 30, 2021 | -$6.07M | – |
| Q4 FY2020 | Dec 31, 2020 | -$6.38M | – |
| Q3 FY2020 | Sep 30, 2020 | -$9.34M | – |
| Q2 FY2020 | Jun 30, 2020 | -$5.45M | – |
| Q1 FY2020 | Mar 31, 2020 | -$7.76M | – |
| Q4 FY2019 | Dec 31, 2019 | -$5.80M | – |
| Q3 FY2019 | Sep 30, 2019 | -$10.50M | – |
| Q4 FY2018 | Dec 31, 2018 | -$7.73M | – |
| Q3 FY2018 | Sep 30, 2018 | -$7.23M | – |
| Q2 FY2018 | Jun 30, 2018 | -$5.35M | – |
| Q1 FY2018 | Mar 31, 2018 | -$5.21M | – |
| Q4 FY2017 | Dec 31, 2017 | -$6.25M | – |
| Q3 FY2017 | Sep 30, 2017 | -$4.74M | – |
See a number that looks wrong?